These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30767390)

  • 1. Mechanism of action of 4-substituted phenols to induce vitiligo and antimelanoma immunity.
    Kammeyer A; Willemsen KJ; Ouwerkerk W; Bakker WJ; Ratsma D; Pronk SD; Smit NPM; Luiten RM
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):540-552. PubMed ID: 30767390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cell-based evaluation of human tyrosinase-mediated metabolic activation of leukoderma-inducing phenolic compounds.
    Nishimaki-Mogami T; Ito S; Cui H; Akiyama T; Tamehiro N; Adachi R; Wakamatsu K; Ikarashi Y; Kondo K
    J Dermatol Sci; 2022 Nov; 108(2):77-86. PubMed ID: 36567223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
    van den Boorn JG; Picavet DI; van Swieten PF; van Veen HA; Konijnenberg D; van Veelen PA; van Capel T; Jong EC; Reits EA; Drijfhout JW; Bos JD; Melief CJ; Luiten RM
    J Invest Dermatol; 2011 Jun; 131(6):1240-51. PubMed ID: 21326294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.
    Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z
    BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
    van den Boorn JG; Melief CJ; Luiten RM
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):673-9. PubMed ID: 21689385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanosomal pH controls rate of melanogenesis, eumelanin/phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells.
    Ancans J; Tobin DJ; Hoogduijn MJ; Smit NP; Wakamatsu K; Thody AJ
    Exp Cell Res; 2001 Aug; 268(1):26-35. PubMed ID: 11461115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune etiology of generalized vitiligo.
    Le Poole IC; Luiten RM
    Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of immune hyporesponsiveness to melanosomal proteins by DHICA-mediated antioxidation: Possible implications for autoimmune vitiligo.
    Liu XM; Zhou Q; Xu SZ; Wakamatsu K; Lei TC
    Free Radic Biol Med; 2011 May; 50(9):1177-85. PubMed ID: 21256957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells.
    Prezioso JA; Damodaran KM; Wang N; Bloomer WD
    Biochem Pharmacol; 1993 Jan; 45(2):473-81. PubMed ID: 8435097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
    Byrne KT; Zhang P; Steinberg SM; Turk MJ
    J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
    Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
    J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why tyrosinase for treatment of melanoma.
    Song YH
    Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes.
    Yang F; Boissy RE
    Pigment Cell Res; 1999 Aug; 12(4):237-45. PubMed ID: 10454291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of melanin synthesis by cystamine in human melanoma cells.
    Qiu L; Zhang M; Sturm RA; Gardiner B; Tonks I; Kay G; Parsons PG
    J Invest Dermatol; 2000 Jan; 114(1):21-7. PubMed ID: 10620110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-regulation of melanin precursors and tyrosinase in human pigment cells: roles of cysteine and glutathione.
    Benathan M; Virador V; Furumura M; Kobayashi N; Panizzon RG; Hearing VJ
    Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):981-90. PubMed ID: 10644002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A convenient screening method to differentiate phenolic skin whitening tyrosinase inhibitors from leukoderma-inducing phenols.
    Ito S; Wakamatsu K
    J Dermatol Sci; 2015 Oct; 80(1):18-24. PubMed ID: 26228294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.